Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best multibagger penny stocks to buy according to analysts.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 4,194,427 | $15,267,714 | +5% | 0.02% |
| 2. | BioImpact Capital Mpm Capital | 2,889,125 | $10,516,415 | 1.82% | |
| 3. | Citadel Investment Group Ken Griffin | 2,317,290 | $8,434,935 | -37% | 0% |
| 4. | Millennium Management Israel Englander | 2,163,499 | $7,875,136 | +80% | 0% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,000,000 | $7,280,000 | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | $19,894.00 | 29,731 | 2019-11-20 | Filing | |
| $3.52 | 15,000 | $52,800.00 | 28,700 | 2019-11-20 | Filing | |
| $3.58 | 27,000 | $96,660.00 | 37,000 | 2019-11-20 | Filing | |
| $3.44 | 50,000 | $172,000.00 | 887,732 | 2019-11-20 | Filing | |
| $3.41 | 50,000 | $170,500.00 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.67 | 41,314 | $151,622.38 | 503,586 | 2025-06-30 | Filing | |
| $4.01 | 15,000 | $60,150.00 | 266,914 | 2025-06-09 | Filing | |
| $3.53 | 13,334 | $47,069.02 | 266,914 | 2025-06-04 | Filing | |
| $1.83 | 46,409 | $84,928.47 | 2,557,921 | 2025-03-03 | Filing | |
| $1.83 | 7,144 | $13,073.52 | 809,090 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,373,961 | $66,881,218 | 0% | |
| 2. | 14,611,466 | $53,185,736 | 0% | |
| 3. | 7,997,153 | $29,109,637 | 0% | |
| 4. | 6,074,458 | $22,115,254 | 0% | |
| 5. | 5,339,654 | $19,436,343 | 0% |
News See All
13 Best Multibagger Penny Stocks to Buy According to Analysts
It’s time to pivot towards micro and small-cap stocks as the US Federal Reserve prepares to cut interest rates.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia Second Quarter 2025 Financial Results. [Operator Instructions] Please be advised that today's call is being recorded.
10 Best Performing Penny Stocks So Far in 2025
By midday Wednesday, July 23, 2025, the Russell 2000 was up 1.57% for the week. This compares to a 0.9% gain for the S&P 500.
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C.
11 Best High Return Penny Stocks to Buy Now
US equity markets are back at all-time highs amid a muted response to new U.S. tariffs and the trade war. The Nasdaq Composite Index, performing relatively well among major U.S.
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential.
13 Stocks Under $5 With High Upside Potential
On July 1, Ralph Schlosstein, Evercore chairman emeritus and BlackRock co-founder, appeared on CNBC's 'Closing Bell Overtime' to discuss his outlook for markets heading into the second half of 2025.
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is among the best growth stocks to invest in for the next 5 years. Akebia Therapeutics, Inc.
12 Small Cap Stocks with High Upside Potential
The trade war saga between the U.S. and China appears to be nearing a conclusion, as China’s Ministry of Commerce shared details on the trade deal on June 27.
Billionaire Hedge Funds
